Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy
NCT07241104Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD4063 in dilated cardiomyopathy (DCM) (8 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events. Started Dec 2025; status: recruiting.
02
Drugs
AZD4063
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT07241104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241104.